Literature DB >> 14217937

SERUM PROTEIN ENHANCEMENT OF ANTIBIOTIC THERAPY IN CRYPTOCOCCOSIS.

M A GORDON, E LAPA.   

Abstract

Keywords:  AMPHOTERICIN B; CRYPTOCOCCOSIS; DRUG THERAPY; EXPERIMENTAL LAB STUDY; GAMMA GLOBULIN; MICE; PHARMACOLOGY; RABBITS

Mesh：

Substances：

Year:  1964        PMID： 14217937     DOI： 10.1093/infdis/114.4.373

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  14 in total

1.  Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide.

Authors:  J E Sanford; D M Lupan; A M Schlageter; T R Kozel
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

Review 3.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

4.  History of medical mycology in the united states.

Authors:  A Espinel-Ingroff
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

5.  Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.

Authors:  Robert A Larsen; Peter G Pappas; John Perfect; Judith A Aberg; Arturo Casadevall; Gretchen A Cloud; Robert James; Scott Filler; William E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 6.  Epidemiological aspects of respiratory mycotic infections.

Authors:  D Pappagianis
Journal:  Bacteriol Rev       Date:  1967-03

7.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

8.  Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.

Authors:  J Mukherjee; L S Zuckier; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.

Authors:  S L Zebedee; R K Koduri; J Mukherjee; S Mukherjee; S Lee; D F Sauer; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.

Authors:  J Mukherjee; L A Pirofski; M D Scharff; A Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.